Australia markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
222.31-2.38 (-1.06%)
At close: 04:00PM EST
222.25 -0.06 (-0.03%)
After hours: 06:40PM EST
Full screen
Trade prices are not sourced from all markets
Previous close224.69
Open221.16
Bid220.05 x 1100
Ask222.30 x 900
Day's range218.38 - 224.91
52-week range214.88 - 468.55
Volume1,505,967
Avg. volume1,597,611
Market cap32.656B
Beta (5Y monthly)0.42
PE ratio (TTM)21.76
EPS (TTM)10.22
Earnings date03 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est284.20
  • Zacks

    Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA

    The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.

  • Zacks

    Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know

    Biogen Inc. (BIIB) closed at $224.69 in the latest trading session, marking a +1.89% move from the prior day.

  • Motley Fool

    Is Biogen a Buy?

    Over the past year, shares of Biogen (NASDAQ: BIIB) have dropped by 13.25% while the S&P 500 has climbed by 23.74%. The biotech's poor performance might come as a bit of a surprise since last year its Alzheimer's disease (AD) drug Aduhelm became the first medicine approved in the U.S. for the illness since 2003. Do the company's recent woes represent a buying opportunity or should investors stay away?